Search clinical trials for: Maraviroc (MVC)

Total 1571 results

National Institute of Allergy and Infectious Diseases...

Completed

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV Infections

United States, Puerto Rico, Thailand, South Africa, Brazil
International Partnership for Microbicides, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

HIV/AIDS

United States
Van Hanh General Hospital

Unknown

BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients (T2DM)

Type 2 Diabetes Mellitus

Vietnam
Hospital General de México Dr. Eduardo Liceaga
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; CCINSHAE... and other collaborators

Terminated

Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults (COMVIVIR)

COVID-19

Mexico
National University of Malaysia
Cytopeutics Sdn. Bhd.

Unknown

Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia

Critical Limb Ischemia

Malaysia
Tehran University of Medical Sciences
Hormozgan University of Medical Sciences

Unknown

Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy

Cerebral Palsy, Spastic

Iran, Islamic Republic of
Ankara University

Completed

The Effect of Different Videolaryngoscopes on Intubation Success in Obese Patients

Difficult Airway, Videolaryngoscopes

Turkey
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

HIV Infections

United States
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

COVID-19 Vaccine

Taiwan
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; HIV Prevention Trials Network

Completed

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

HIV Infection

United States, Puerto Rico
Taoyuan General Hospital
Medigen Vaccine Biologics Corp.

Recruiting

A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

COVID-19 Vaccine

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

HIV Infections | Kidney Diseases

United States
Association Pour la Recherche en Infectiologie

Unknown

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients (NNNB)

HIV

France
Istanbul University

Completed

Hemodynamic Responses of Different Laryngoscopes

Heart Rate and Rhythm Disorders | Blood Pressures | Oxygen Disorders

Turkey
Abramson Cancer Center of the University of Pennsylvania

Completed

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Hematopoietic Stem Cell Transplantation | Graft-versus-host Disease
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
ViiV Healthcare
Pfizer

No longer available

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Human Immunodeficiency Virus (HIV)
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19

COVID-19

Taiwan
Ottawa Hospital Research Institute
Pfizer

Completed

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (RIFAMARA)

HIV Infection | HIV-1 Infection | Mycobacterium Avium Complex (MAC)

Canada
Kirby Institute

Completed

MARCH Vascular Endothelium Substudy (MARCH VE)

Cardiovascular Disease

Argentina, Australia, Germany, Thailand
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

Covid19 Vaccine

Taiwan
International Partnership for Microbicides, Inc.

Withdrawn

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

HIV Infections
Indonesia University
Dr Cipto Mangunkusumo General Hospital

Unknown

BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients

T2D

Indonesia
University Hospital, Caen
Novespace

Unknown

Muscular Force Generation in Microgravity (ForceGeneratio)

Maximum Voluntary Contraction

France
International Partnership for Microbicides, Inc.

Completed

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

HIV Infections

United States
St Stephens Aids Trust

Completed

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study (CINAMMON)

HIV

United Kingdom
Emory University

Completed

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women (MVC-PREP)

HIV

United States
French National Agency for Research on AIDS and...
Pfizer

Completed

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration (145 MARIMUNO)

HIV Infections | HIV Infection

France
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
Medigen Vaccine Biologics Corp.
Coalition for Epidemic Preparedness Innovations

Completed

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

COVID-19 Vaccine

Taiwan
University Of Perugia

Completed

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Inflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other Conditions

Italy
Germans Trias i Pujol Hospital

Completed

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

HIV Infections | HIV

Spain
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
ViiV Healthcare

Completed

Expanded Access Program for Maraviroc At Multiple Centers

HIV Infections

Canada, United States, Spain, Switzerland, Malaysia, France, Italy, Portugal, Puerto Rico, Mexico, Australia, Ireland, Romania, Greece, United Kingdom, Argentina, Austria, Belgium, Chile, Costa Rica, Dominican Republic, Germany, Hong... and more
Bactiguard AB
Danderyd Hospital

Terminated

BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden (IMPROWE)

Catheter-Related Infections | Catheter Bacteraemia | Vascular Access Complication | Catheter Complications | Catheter Site Discomfort | Catheter Blockage | Catheter Thrombosis

Sweden
Fundación Pública Andaluza para la gestión de la...

Completed

Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) (COVIMAR)

Virus Diseases

Spain
Centre hospitalier de l'Université de Montréal...
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Healthy

Canada
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
Sam Houston State University

Terminated

Two-Session Couples Class to Improve Relationship Health

Stress

United States
University of Hawaii
Pfizer

Completed

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

HIV Infections

United States
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
University of California, San Francisco
Pfizer; Stanford University; amfAR, The Foundation for AIDS Research; Case Western... and other collaborators

Completed

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

HIV Infection

United States
ANRS, Emerging Infectious Diseases
Pfizer

Completed

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

HIV-1 Infection | AIDS

France
Asociacion para el Estudio de las Enfermedades...

Completed

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term (TROPISMVC)

HIV Infections

Spain
S.F.L. van Lelyveld
Pfizer; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van... and other collaborators

Completed

Maraviroc Immune Recovery Study (MIRS)

HIV Infections

Netherlands
Hospital Universitario Infanta Leonor
Hospital Clinic of Barcelona; ViiV Healthcare

Terminated

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID)

COVID-19

Spain
Tel-Aviv Sourasky Medical Center

Completed

Safety of Maraviroc for Post-stroke Depression (MRV-PSD)

Post-stroke Depression

Israel
ViiV Healthcare
Pfizer; Copenhagen HIV Programme

Completed

EuroSIDA As An External Comparator To MOTIVATE Trials

HIV | AIDS
ViiV Healthcare
Pfizer

Completed

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Human Immunodeficiency Virus (HIV) Infection

Singapore
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden

Search clinical trials for: Maraviroc (MVC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations